Intellia Therapeutics Inc (NASDAQ: NTLA) started the day on Wednesday, with a price decrease of -8.45% at $12.02, before settling in for the price of $13.13 at the close. Taking a more long-term approach, NTLA posted a 52-week range of $12.47-$34.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 12.09%. Meanwhile, its Annual Earning per share during the time was -22.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 1.96%. This publicly-traded company’s shares outstanding now amounts to $101.80 million, simultaneously with a float of $100.10 million. The organization now has a market capitalization sitting at $1.22 billion. At the time of writing, stock’s 50-day Moving Average stood at $15.88, while the 200-day Moving Average is $21.78.
Intellia Therapeutics Inc (NTLA) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Intellia Therapeutics Inc’s current insider ownership accounts for 1.71%, in contrast to 92.39% institutional ownership. According to the most recent insider trade that took place on Oct 02 ’24, this organization’s VP, Chief Accounting Officer sold 2,012 shares at the rate of 19.01, making the entire transaction reach 38,248 in total value, affecting insider ownership by 47,012. Preceding that transaction, on Jul 01 ’24, Company’s EVP, Chief Technical Officer sold 405 for 22.93, making the whole transaction’s value amount to 9,287. This particular insider is now the holder of 71,470 in total.
Intellia Therapeutics Inc (NTLA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.37 per share during the current fiscal year.
Intellia Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 1.96% and is forecasted to reach -5.49 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 30.00% through the next 5 years, which can be compared against the -22.30% growth it accomplished over the previous five years trading on the market.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Let’s observe the current performance indicators for Intellia Therapeutics Inc (NTLA). It’s Quick Ratio in the last reported quarter now stands at 6.73. The Stock has managed to achieve an average true range (ATR) of 0.97. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 28.41.
In the same vein, NTLA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.45, a figure that is expected to reach -1.34 in the next quarter, and analysts are predicting that it will be -5.49 at the market close of one year from today.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
If we take a close look at the recent performances of Intellia Therapeutics Inc (NASDAQ: NTLA), its last 5-days Average volume was 2.6 million that shows progress from its year to date volume of 1.77 million. During the previous 9 days, stock’s Stochastic %D was recorded 19.67% While, its Average True Range was 0.94.
Raw Stochastic average of Intellia Therapeutics Inc (NTLA) in the period of the previous 100 days is set at 0.78%, which indicates a major fall in contrast to 2.92% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 68.49% that was lower than 68.93% volatility it exhibited in the past 100-days period.
